K Lacombe

Summary

Country: France

Publications

  1. ncbi HIV and viral hepatitis coinfections: advances and challenges
    Karine Lacombe
    Service de Maladies Infectieuses et Tropicales, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France
    Gut 61:i47-58. 2012
  2. ncbi Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus
    Sarah Maylin
    Laboratoire de Virologie, Hopital Saint Louis, AP HP, Paris, France
    Clin Vaccine Immunol 19:242-8. 2012
  3. ncbi Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients
    Karine Lacombe
    INSERM UMR S707, Paris, France
    Antivir Ther 13:705-13. 2008
  4. ncbi [HIV infection and comorbidities]
    Karine Lacombe
    Service de Maladies Infectieuses, Hopital Saint Antoine, 75571 Paris Cedex 12
    Rev Prat 56:995-1004. 2006
  5. ncbi Drug-resistant and immune-escape HBV mutants in HIV-infected hosts
    Karine Lacombe
    INSERM, UMR S707, Paris, France
    Antivir Ther 15:493-7. 2010
  6. ncbi HIV/hepatitis B virus co-infection: current challenges and new strategies
    K Lacombe
    INSERM UMR S, Paris, France
    J Antimicrob Chemother 65:10-7. 2010
  7. ncbi Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate
    Karine Lacombe
    INSERM U707, Universite Pierre et Marie Curie, 27 rue de Chaligny, 75571 Paris Cedex 12, France
    AIDS 19:907-15. 2005
  8. ncbi Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus
    A Boyd
    INSERM, Paris and UMR S707, Universite Pierre et Marie Curie PARIS6, Paris, France
    J Viral Hepat 17:65-76. 2010
  9. ncbi The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
  10. ncbi Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients
    M A Loko
    INSERM, U897, ISPED, Universite Victor Segalen, Bordeaux, France
    J Viral Hepat 18:e307-14. 2011

Detail Information

Publications30

  1. ncbi HIV and viral hepatitis coinfections: advances and challenges
    Karine Lacombe
    Service de Maladies Infectieuses et Tropicales, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France
    Gut 61:i47-58. 2012
    ....
  2. ncbi Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus
    Sarah Maylin
    Laboratoire de Virologie, Hopital Saint Louis, AP HP, Paris, France
    Clin Vaccine Immunol 19:242-8. 2012
    ..078). In conclusion, the Elecsys assay, with automatic on-board dilution, is capable of quantifying serum HBsAg levels in HIV-HBV-coinfected patients, with very high correlation with the Architect assay...
  3. ncbi Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients
    Karine Lacombe
    INSERM UMR S707, Paris, France
    Antivir Ther 13:705-13. 2008
    ..Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfected patients...
  4. ncbi [HIV infection and comorbidities]
    Karine Lacombe
    Service de Maladies Infectieuses, Hopital Saint Antoine, 75571 Paris Cedex 12
    Rev Prat 56:995-1004. 2006
    ....
  5. ncbi Drug-resistant and immune-escape HBV mutants in HIV-infected hosts
    Karine Lacombe
    INSERM, UMR S707, Paris, France
    Antivir Ther 15:493-7. 2010
    ..For patients coinfected with HIV, hepatitis B treatment options that aim to reduce the risk of HBV mutations from emerging must be seriously considered, not only from clinical but also public health perspectives...
  6. ncbi HIV/hepatitis B virus co-infection: current challenges and new strategies
    K Lacombe
    INSERM UMR S, Paris, France
    J Antimicrob Chemother 65:10-7. 2010
    ....
  7. ncbi Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate
    Karine Lacombe
    INSERM U707, Universite Pierre et Marie Curie, 27 rue de Chaligny, 75571 Paris Cedex 12, France
    AIDS 19:907-15. 2005
    ..The long-term impact of tenofovir disoproxil fumarate (TDF) on hepatitis B virus (HBV) replication has not yet been studied in HIV-HBV-co-infected patients...
  8. ncbi Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus
    A Boyd
    INSERM, Paris and UMR S707, Universite Pierre et Marie Curie PARIS6, Paris, France
    J Viral Hepat 17:65-76. 2010
    ..Peaks and rebounds from undetectable hepatitis B, C and/or D viremia warrant closer follow-up in this patient population. HDV-replication was uncontrolled even with antiviral treatment...
  9. ncbi The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
    ..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
  10. ncbi Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients
    M A Loko
    INSERM, U897, ISPED, Universite Victor Segalen, Bordeaux, France
    J Viral Hepat 18:e307-14. 2011
    ..Antiretroviral drugs with strong mitochondrial toxicity (e.g. didanosine) or a major effect on glucose metabolism should be avoided...
  11. ncbi Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician
    P Roux
    INSERM, U912 SE4S, Marseille, France
    Drug Alcohol Depend 116:228-32. 2011
    ....
  12. ncbi Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: performance of the METAVIR score assessed on virtual slides
    D Wendum
    APHP, Hopital St Antoine, Service d Anatomie Pathologique, Paris, France
    J Clin Pathol 62:361-3. 2009
    ..The METAVIR score, which is the most widely used score in France, was specifically elaborated and evaluated in chronic hepatitis C and has never been validated in HIV-hepatitis virus B (HBV) co-infected patients...
  13. ncbi Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008
    L Michel
    INSERM U669, Paris, France
    J Viral Hepat 17:650-60. 2010
    ....
  14. ncbi How to improve the quality of a disease management program for HIV-infected patients using a computerized data system. The Saint-Antoine Orchestra program
    F Fonquernie
    AP HP, Department of Infectious and Tropical Diseases, Saint Antoine Hospital, Paris, France
    AIDS Care 22:588-96. 2010
    ....
  15. ncbi Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort
    Marc Arthur Loko
    INSERM, U593, Bordeaux, France
    Am J Gastroenterol 103:1973-80. 2008
    ..Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking...
  16. ncbi [Early diagnosis and prevention of comorbidities among HIV-infected patients: the Orchestra Saint-Antoine Program]
    L Fonquernie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Universite Pierre et Marie Curie Paris VI, APHP, 184, 75012 Paris, France
    Med Mal Infect 37:S229-36. 2007
    ..The Saint-Antoine Orchestra Program aims at improving the clinical management of HIV-infected patients through access to care, prevention and early diagnosis of comorbidities...
  17. ncbi Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease
    Patrick Soussan
    Pathogenèse des Hépatites Virales B et Immunothérapie, Institut National de la Santé et de la Recherche Médicale U845, Paris, France
    J Infect Dis 198:218-25. 2008
    ..The present study was designed to quantify the expression of defective HBV (dHBV) and wild-type HBV (wtHBV) genomes in the serum of patients with HBV infection and its relation to the severity of liver disease...
  18. ncbi Use of infliximab to treat psoriatic arthritis in HIV-positive patients
    Jeremie Sellam
    Rheumatology Department, Saint Antoine Teaching Hospital, AP HP, Paris, France
    Joint Bone Spine 74:197-200. 2007
    ..Potential long-term effects such as opportunistic infections, malignancies, and loss of HIV control need to be evaluated...
  19. ncbi Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy
    Olivia Chauvel
    AP HP, Hopital Saint Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France
    Antivir Ther 12:1115-26. 2007
    ..Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients...
  20. ncbi A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient
    Karine Lacombe
    INSERM U707, , , , Paris, F-75012 France
    AIDS 20:2229-31. 2006
    ..This observation suggests that careful monitoring of co-infected patients is required to diagnose HBV resistance to nucleos(t)ide analogues, and that tenofovir may be active at least against some of the adefovir-resistant strains...
  21. ncbi Determinants of adherence to non-occupational post HIV exposure prophylaxis
    Karine Lacombe
    Service de Maladies Infectieuses et Tropicales, Paris, France
    AIDS 20:291-4. 2006
    ..3, 2.02-87.54] and oral sexual intercourse (OR 8.35, 1.66-41.99). Compliance with prophylactic antiretroviral therapy can be increased by addressing social and psychological barriers to adherence...
  22. ncbi Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues
    Laurent Fonquernie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, 184 rue du Faubourg Saint Antoine, 75012 Paris, France
    Trans R Soc Trop Med Hyg 100:282-4. 2006
    ..This immunovirological discordance was due to failure of the viral load assay and infection by an unknown HIV-2 subtype. Treatment was probably suboptimal, leading to the selection of several resistance mutations and treatment failure...
  23. ncbi Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen
    Karine Lacombe
    Assistance Publique, , , Service de Maladies Infectieuses et Tropicales, Paris F-75012, France
    AIDS 19:1107-8. 2005
    ..Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg...
  24. ncbi Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    AIDS 21:1323-31. 2007
    ..To describe the characteristics of hepatitis B (HBV) infection in HIV-infected patients and the impact of anti-HBV treatments...
  25. ncbi Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus
    Karine Lacombe
    INSERM, UMR S707, Paris, F 75012, France
    AIDS 21:2546-9. 2007
    ..02, 95% CI = 1.03-97.42 for HBV-HCV-HDV, compared to OR = 1.76, 95% CI = 0.50-6.17 for HBV alone]. Co-treatment of other multiple viral hepatitis infections should also be taken into consideration, especially in the case of chronic HDV...
  26. ncbi Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy
    Franck Boccara
    Department of Pharmacology, , , INSERM 652, , Paris, France
    AIDS 20:2395-8. 2006
    ..Age and body mass index were independent determinants of IMT of the CCA. Mean arterial pressure, age, duration of HIV infection and protease inhibitor exposure determined aortic stiffness...
  27. ncbi Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV
    Karine Lacombe
    INSERM U707, Paris, France
    AIDS 20:419-27. 2006
    ....
  28. ncbi Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough
    Marie-Caroline Meyohas
    AIDS 18:1966-8. 2004
  29. ncbi Acute hepatic cytolysis in an HIV-infected patient taking atazanavir
    Serge P Eholié
    AIDS 18:1610-1. 2004
  30. ncbi [HIV infection]
    Karine Lacombe
    Service de Maladies Infectieuses et Tropicales, , 75012 Paris
    Rev Prat 53:1479-87. 2003